← Leaderboards
Natalie Vokes
University Of Tx Md Anderson Can Ctr
$989,037
Attributed
$1,978,073
Total exposure
1
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $676.6K · FY2023–25$1M$750K$500K$250K$0
'23
'24
'25
Funding mix
By agency
NIH$1,978,073 · 1
By mechanism
R01$1,978,073 · 1
Top collaborators
- Jia Wu3 shared
Most similar at University Of Tx Md Anderson Can Ctr
Same institution · by research overlap
- Tina Cascone$2,250,345
- Gregory A Lizee$3,884,952
- Meghan Sri Karuturi$1,252,885
- Michael J Overman$2,432,364
- Di Zhao$3,648,377
Others in their field
Other Rising Stars on “Clinical Predictors”
- Donald Lloyd-Jones · Boston University (Charles River Campus)$8,894,939
- Matthew Morrow Engelhard · Duke University$7,519,665
- Agustin G Yip · Albert Einstein College Of Medicine$6,090,308
- Pamela Lutsey · University Of Minnesota$3,992,605
- Trevor Adam Crowell · Henry M. Jackson Fdn For The Adv Mil/Med$3,822,251
- Josef Coresh · Johns Hopkins University$3,770,641
Research focus
Clinical PredictorsBench To BedsideAlgorithmsBiological MarkersBiologyBiopsyBloodAnalytical ToolBlood SpecimenBlood TreatmentCancer BiologyCancer CenterCancer GenomicsCancer PatientCheckpoint TherapyChemotherapyBiologicalClassificationClinical Assay DevelopmentClinical DataClinical Decision-MakingClinically RelevantClinical ManagementCode
Grant awards (3)
Integrated blood and radiomic subtyping to guide immunotherapy treatment selection and early response assessment in metastatic non-small cell lung cancer$665,352
R01 · FY2025 · CA · contact PI
Integrated blood and radiomic subtyping to guide immunotherapy treatment selection and early response assessment in metastatic non-small cell lung cancer$636,160
R01 · FY2024 · CA · contact PI
Integrated blood and radiomic subtyping to guide immunotherapy treatment selection and early response assessment in metastatic non-small cell lung cancer$676,561
R01 · FY2023 · CA · contact PI